Follow G1 Therapeutics as it advances trilaciclib in Phase 3 PRESERVE 2 trial for metastatic triple-negative breast cancer. Updates on trial progress, interim analysis, and potential FDA filing in 2024.
BioXcel Therapeutics shares surge 25.1% as the company terminates its proposed public offering and shifts focus to upcoming FDA meeting and Phase 3 trial.
LCI Industries faces a 6% Y/Y revenue dip in Q4 FY23, reaching $837.5 million, impacted by reduced North American marine production and lower selling prices. Despite challenges, Aftermarket net sales show a 10% Y/Y increase, signaling stability in distribution channels.
CEO Jason Lippert highlights product launches driving growth, including independent suspension axles and new window systems.
AutoNation reports Q4 earnings beat but sees share price decline as lower used vehicle sales impact gross profit, despite strong new vehicle sales growth.
Ecolab shines in Q4 FY23, boasting $3.938 billion in sales, driven by growth across key segments. CEO Christophe Beck anticipates continued strong performance, projecting solid earnings growth for FY24.